Milind M. Javle

机构：The University of Texas MD Anderson Cancer Center · ORCID：0000-0001-9158-0941

发表论文 754 篇 · 总被引 23348 次 · h-index 75

代表论文

Personalized Therapy in Advanced Cholangiocarcinoma: Contemporary Treatment Approaches and Future Directions (2026 · JCO Oncology Practice)
Supplementary Data1 from A Randomized Phase II Study of Combination Atezolizumab and Varlilumab (CDX-1127) with or without Cobimetinib in Previously Treated Unresectable Biliary Tract Cancer (2026)
Data from A Randomized Phase II Study of Combination Atezolizumab and Varlilumab (CDX-1127) with or without Cobimetinib in Previously Treated Unresectable Biliary Tract Cancer (2026)
Supplementary Data2 from A Randomized Phase II Study of Combination Atezolizumab and Varlilumab (CDX-1127) with or without Cobimetinib in Previously Treated Unresectable Biliary Tract Cancer (2026)
Table S3 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer (2026)
Table S2 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer (2026)